TD Waterhouse Canada Inc. Sells 120,736 Shares of Gilead Sciences, Inc. $GILD

TD Waterhouse Canada Inc. lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 82.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,615 shares of the biopharmaceutical company’s stock after selling 120,736 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Gilead Sciences were worth $2,871,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GILD. Activest Wealth Management grew its position in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the period. GoalVest Advisory LLC increased its stake in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares in the last quarter. Harbor Asset Planning Inc. acquired a new position in Gilead Sciences in the 2nd quarter valued at $27,000. Putney Financial Group LLC lifted its stake in shares of Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 94 shares in the last quarter. Finally, Colonial Trust Advisors boosted its holdings in shares of Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Trading Up 1.3%

NASDAQ:GILD opened at $126.64 on Friday. Gilead Sciences, Inc. has a 12-month low of $88.57 and a 12-month high of $128.70. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm has a market capitalization of $157.12 billion, a P/E ratio of 25.23, a P/E/G ratio of 0.81 and a beta of 0.32. The business has a 50 day simple moving average of $118.48 and a 200 day simple moving average of $113.54.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same period last year, the firm posted $2.02 earnings per share. The business’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s payout ratio is currently 48.99%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on GILD shares. Argus raised their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Truist Financial reaffirmed a “buy” rating and set a $145.00 price objective (up from $127.00) on shares of Gilead Sciences in a research report on Monday, November 3rd. Scotiabank assumed coverage on Gilead Sciences in a report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price objective on the stock. Finally, BMO Capital Markets raised their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a report on Monday, October 20th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $130.45.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $125.23, for a total value of $313,075.00. Following the transaction, the chief financial officer owned 154,555 shares of the company’s stock, valued at $19,354,922.65. This trade represents a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the transaction, the insider owned 107,193 shares of the company’s stock, valued at approximately $13,491,310.98. The trade was a 20.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 125,146 shares of company stock valued at $15,148,441. Corporate insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.